PRO MEDICUS LIMITED (PME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PME

PME - PRO MEDICUS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.01
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS | ALL-TECH

Pro Medicus is an imaging IT company providing a range of radiology software and services, medical accounting and clinical reporting to the health care sector. Founded in 1983, the company listed on the ASX in 2000.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$127.60

26 Feb
2026

11.690

OPEN

$120.10

10.09%

HIGH

$127.67

795,477

LOW

$120.10

TARGET
$259.00 103.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PME: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 110.3 185.4 xxx
DPS (cps) xxx 55.0 67.8 xxx
EPS Growth xxx 39.1% 68.1% xxx
DPS Growth xxx 37.5% 23.3% xxx
PE Ratio xxx N/A 70.1 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 49.9% 36.6% xxx

Dividend yield today if purchased 3 years ago: 0.90%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.42

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 30.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx110.3
DPS All xxxxxxxxxxxxxxx55.0
Sales/Revenue xxxxxxxxxxxxxxx213.0 M
Book Value Per Share xxxxxxxxxxxxxxx246.0
Net Operating Cash Flow xxxxxxxxxxxxxxx118.9 M
Net Profit Margin xxxxxxxxxxxxxxx54.10 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx51.82 %
Return on Invested Capital xxxxxxxxxxxxxxx51.46 %
Return on Assets xxxxxxxxxxxxxxx38.65 %
Return on Equity xxxxxxxxxxxxxxx51.82 %
Return on Total Capital xxxxxxxxxxxxxxx70.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx69.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx2 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx209 M
Price To Book Value xxxxxxxxxxxxxxx115.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.4 M
Capex % of Sales xxxxxxxxxxxxxxx3.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

13/02/2026

1

Outperform

$244.00

91.22%

Pro Medicus' 1H26 miss was driven by a revenue skew to the second half, Macquarie notes, as well as higher than expected employee expenses, including one-off incentive payments.

The company sees AI as a significant tailwind rather than a disruptive threat, adding productivity gains over and above the existing more than 25% gains with Visage 7. Pro Medicus has launched generative AI tools such as error checking and dictation with additional reporting tools incoming.

Macquarie sees this supporting fee-per-click increases for both new and renewed contacts which have historically been high single digits. Pro Medicus' scalable model, contract momentum and expanding multi-ology pipeline support growth despite heightened market sensitivity.

Target falls to $244.00 from $291.30, Outperform retained.

FORECAST
Macquarie forecasts a full year FY26 dividend of 72.00 cents and EPS of 145.00 cents.
Macquarie forecasts a full year FY27 dividend of 90.00 cents and EPS of 179.00 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Moelis

17/02/2026

3

Hold

$141.04

10.53%

Pro Medicus’ 1H26 result missed expectations held by Moelis, though fundamentals remain intact, according to the broker.

Revenue of $124.8m rose by 28%, with NPAT rising 29%, but both were below consensus on contract timing, explain the analysts. It's noted the earnings (EBIT) margin improved to 73%, up from 72% in H1 FY25.

The broker trims its FY26-28 EPS forecasts by between -2-8% on ramp-up timing and FX, partly offset by repricing. It believes AI risk is limited given regulation, proprietary technology and strong implementation capability.

The analysts expect around 30% annual growth in revenue, supported by a solid pipeline and low US market share.

Moelis retains a Hold rating. The target is lowered to $141.04 from $325.82.

FORECAST
Moelis forecasts a full year FY26 dividend of 67.00 cents and EPS of 139.80 cents.
Moelis forecasts a full year FY27 dividend of 96.00 cents and EPS of 189.50 cents.
Access Extra Coverage Research History >

PME STOCK CHART

FNArena News on PME

1
Rudi’s View: Positives From February Results

Feb 26 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Feb 18, 2026

Feb 18 2026 - Daily Market Reports
3
Rudi’s View: Is Higher Volatility Now A Permanent Feature?

Feb 18 2026 - Rudi's View
4
Australian Broker Call *Extra* Edition – Feb 17, 2026

Feb 17 2026 - Daily Market Reports
5
Weekly Ratings, Targets, Forecast Changes – 13-02-26

Feb 16 2026 - Weekly Reports

Latest Medical Equipment & Devices News

1
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
4
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
5
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
6
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
7
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
8
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
9
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
10
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia